Hydroxychloroquine, sold under the brand name Plaquenil and often abbreviated HCQ, is a genuine disease-modifying drug for rheumatoid arthritis, though a modest one. This article explains what rheumatoid arthritis actually is, where hydroxychloroquine fits among the treatments available, what the clinical trial evidence actually shows, how it is dosed, how long it takes to produce a benefit, and what monitoring a patient should expect while taking it.
What Rheumatoid Arthritis Actually Is
Rheumatoid arthritis (RA) is a chronic autoimmune disease in which the immune system mistakenly attacks the synovium, the thin lining of the joints. The result is inflammation, swelling, stiffness, and, if left untreated, progressive destruction of cartilage and bone. It typically affects joints symmetrically, most often the small joints of the hands, wrists, and feet, and morning stiffness lasting more than thirty minutes is a hallmark symptom. Fatigue, low-grade fever, and involvement of other organs, including the lungs, eyes, and blood vessels in more severe cases, can accompany the joint disease.
The precise cause is not fully understood, but RA arises from an interaction between genetic susceptibility (certain HLA-DRB1 gene variants are well documented) and environmental triggers, of which cigarette smoking has the strongest and most consistently reproduced association. Periodontal disease and specific gut and lung bacteria have also been implicated in triggering the abnormal immune response, though this remains an active area of research rather than settled fact. RA affects roughly 1 percent of adults worldwide and is two to three times more common in women, often emerging between ages 30 and 60.
Where Hydroxychloroquine Fits Among RA Treatments
There is no single "best" treatment for rheumatoid arthritis; treatment is matched to disease severity, and current American College of Rheumatology (ACR) guidance, most recently updated in 2021, recommends methotrexate as the preferred first-line conventional synthetic DMARD for most patients with moderate-to-high disease activity. Hydroxychloroquine belongs to the same broad class of conventional synthetic DMARDs but is considered one of the mildest members of that class. It is most often reached for in three situations: genuinely mild or low-activity RA where a gentler drug is appropriate; palindromic or very early disease where aggressive therapy may not yet be warranted; and, most commonly in modern practice, as one component of combination therapy alongside methotrexate and sulfasalazine, a regimen often called "triple therapy."
Hydroxychloroquine's origins trace back to quinine, the antimalarial compound purified from the bark of the cinchona tree, a reminder that a great deal of modern pharmacology has simply refined what was already present in the natural world. Its mechanism in autoimmune disease is not fully mapped, but it is believed to work by accumulating in the acidic compartments of immune cells, raising their internal pH, and thereby interfering with antigen processing and the signaling of certain toll-like receptors that drive inflammation. Unlike methotrexate or biologic agents, it does not suppress the immune system broadly, which accounts for both its milder efficacy and its comparatively favorable safety profile.
The Clinical Trial Evidence
The evidence base for hydroxychloroquine in RA is real but should be described honestly for what it is: solid for symptom improvement, weaker for preventing joint damage. The HERA study (Hydroxychloroquine in Early Rheumatoid Arthritis), a multicenter Canadian randomized placebo-controlled trial published in the Journal of Rheumatology in 1995, found that patients with early RA on hydroxychloroquine had significantly greater improvement in tender and swollen joint counts, physician and patient global assessments, and inflammatory markers over nine months compared with placebo. It did not, however, demonstrate a significant slowing of radiographic joint damage, an important limitation.
A Cochrane systematic review pooling several placebo-controlled trials from the 1990s reached a similar conclusion: hydroxychloroquine produces a real, statistically significant reduction in disease activity compared with placebo, but the effect size is smaller than that seen with methotrexate or sulfasalazine, and evidence for preventing structural progression is limited. This is why hydroxychloroquine is rarely used alone in patients with moderate or high disease activity today.
Its more important modern role comes from combination trials. The RACAT trial, a National Institutes of Health-funded, VA-led randomized study published in the New England Journal of Medicine in 2013 by O'Dell and colleagues, compared triple therapy (methotrexate, sulfasalazine, and hydroxychloroquine together) against methotrexate plus a biologic (etanercept) in patients who had not responded adequately to methotrexate alone. Triple therapy was found to be non-inferior, producing similar improvements in disease activity scores at 24 and 48 weeks, and patients who did not respond to one strategy did comparably well after switching to the other. This trial gave hydroxychloroquine a durable, evidence-supported place in combination regimens, including for patients and physicians who prefer to try a non-biologic approach before escalating to more expensive or more immunosuppressive biologic therapy.
Dosing and What to Expect
Hydroxychloroquine is available as 200 mg tablets. Historically it was often prescribed at a flat 400 mg per day (200 mg twice daily), but current best practice, following a 2016 revision of retinal safety guidance from the American Academy of Ophthalmology, is to base the dose on the patient's actual body weight, generally not exceeding 5 mg per kilogram of real body weight per day. In practice this means many adult patients end up on 200 mg to 300 mg daily rather than the older standard dose, and rheumatologists now calculate this individually rather than prescribing a one-size-fits-all regimen.
Patients should expect hydroxychloroquine to work slowly. Unlike NSAIDs or corticosteroids, which can relieve symptoms within days, and unlike methotrexate, which often shows measurable benefit within four to eight weeks, hydroxychloroquine's anti-inflammatory effect typically builds gradually over three to six months, with some patients not reaching the full benefit until closer to the six-month mark. Because of this delayed onset, it is common for a physician to prescribe a short-term bridge, such as a low-dose corticosteroid or an NSAID, while waiting for hydroxychloroquine or a combination regimen to take full effect. Patients who stop the drug after only a few weeks because they "don't feel anything" are often stopping before it has had a fair trial; this is a conversation worth having directly with the prescribing physician rather than deciding unilaterally.
Safety, Monitoring, and Special Considerations
Hydroxychloroquine's most distinctive risk is not to the joints but to the eyes. Long-term use can, in a minority of patients, cause a retinal toxicity that in advanced stages is irreversible and can affect vision. A widely cited retrospective study by Melles and Marmor, published in JAMA Ophthalmology in 2014 using Kaiser Permanente patient data, found an overall retinopathy prevalence of roughly 7.5 percent among long-term users, with the risk rising sharply after ten years of continuous use and at higher daily doses relative to body weight. This finding directly prompted the 2016 revision to weight-based dosing limits and the current recommendation that patients undergo a baseline ophthalmologic examination before starting the drug, followed by annual screening after five years of use (or sooner in patients with additional risk factors such as kidney disease or pre-existing retinal disease). This is a genuine and non-trivial risk, but it is also a manageable one when patients keep their scheduled eye exams, which is a responsibility worth taking seriously rather than a formality to skip.
Other side effects are generally milder: gastrointestinal upset, skin rash, and a bluish-gray skin discoloration with prolonged use are the most common. Rare but serious effects include cardiomyopathy and a skeletal muscle or nerve toxicity (neuromyopathy), both uncommon and typically associated with long-term, higher-dose use.
One point deserves particular emphasis for readers planning a family: hydroxychloroquine is one of the few DMARDs considered compatible with pregnancy and breastfeeding, based on decades of accumulated experience treating pregnant women with lupus and RA, whereas methotrexate is a known teratogen and is contraindicated in pregnancy. Many rheumatologists specifically continue hydroxychloroquine through pregnancy to keep maternal disease controlled while protecting the developing child, a decision that should always be made jointly between the patient and her physician based on her individual case. Patients should never adjust or stop an RA medication around a pregnancy without that direct conversation.
Key takeaway: Hydroxychloroquine is a genuinely evidence-supported but modest DMARD, best suited to mild rheumatoid arthritis or as one part of combination therapy, requiring patience for its slow onset and regular eye monitoring, and its decades-long record makes it one of the few RA drugs considered safe to continue through pregnancy.